[
  {
    "ts": "2025-12-19T14:51:37+00:00",
    "headline": "I’ll Play, Says Jim Cramer About Bristol-Myers (BMY)",
    "summary": "We recently published 12 Stocks on Jim Cramer’s Radar. Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks aon Jim Cramer’s radar. Bristol-Myers Squibb Company (NYSE:BMY) is one of the largest pharmaceutical companies in the world. The firm has seen some attention from analysts in December. For instance, Jefferies reiterated a Buy rating and a $68 […]",
    "url": "https://finance.yahoo.com/news/ll-play-says-jim-cramer-145137156.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "88cb8784-89b6-3eaa-9dab-dbb33037452d",
      "content": {
        "id": "88cb8784-89b6-3eaa-9dab-dbb33037452d",
        "contentType": "STORY",
        "title": "I’ll Play, Says Jim Cramer About Bristol-Myers (BMY)",
        "description": "",
        "summary": "We recently published 12 Stocks on Jim Cramer’s Radar. Bristol-Myers Squibb Company (NYSE:BMY) is one of the stocks aon Jim Cramer’s radar. Bristol-Myers Squibb Company (NYSE:BMY) is one of the largest pharmaceutical companies in the world. The firm has seen some attention from analysts in December. For instance, Jefferies reiterated a Buy rating and a $68 […]",
        "pubDate": "2025-12-19T14:51:37Z",
        "displayTime": "2025-12-19T14:51:37Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/67016191d6d2df48fd6f8c9ec632b347",
          "originalWidth": 1920,
          "originalHeight": 1186,
          "caption": "I'll Play, Says Jim Cramer About Bristol-Myers (BMY)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vJ7lKbloSPByVfgD_gqgZg--~B/aD0xMTg2O3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/67016191d6d2df48fd6f8c9ec632b347.cf.webp",
              "width": 1920,
              "height": 1186,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/szs6fG45A8w_rlV8N_NBzA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/67016191d6d2df48fd6f8c9ec632b347.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ll-play-says-jim-cramer-145137156.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ll-play-says-jim-cramer-145137156.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T13:02:12+00:00",
    "headline": "Why Cytokinetics CEO Is Optimistic As FDA Deadline On Aficamten Looms",
    "summary": "Cytokinetics is on the cusp of its first FDA approval, analysts say, leading up to the agency's decision date for the drug called aficamten.",
    "url": "https://www.investors.com/news/technology/cytokinetics-ceo-robert-blum-fda-decision-aficamten-ohcm/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "8d5f8911-c1c1-3569-b3ab-1cdcf9af25af",
      "content": {
        "id": "8d5f8911-c1c1-3569-b3ab-1cdcf9af25af",
        "contentType": "STORY",
        "title": "Why Cytokinetics CEO Is Optimistic As FDA Deadline On Aficamten Looms",
        "description": "",
        "summary": "Cytokinetics is on the cusp of its first FDA approval, analysts say, leading up to the agency's decision date for the drug called aficamten.",
        "pubDate": "2025-12-19T13:02:12Z",
        "displayTime": "2025-12-19T13:02:12Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/8d5f8911-c1c1-3569-b3ab-1cdcf9af25af/why-cytokinetics-ceo-is.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/a49294d1547dac5f94f8ff5ce500b4a7",
          "originalWidth": 1000,
          "originalHeight": 511,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fxptB0Mc.7PjpZxZUhrHhg--~B/aD01MTE7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/a49294d1547dac5f94f8ff5ce500b4a7.cf.webp",
              "width": 1000,
              "height": 511,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cE7IU62RGFIGAiy9bTHdmw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/a49294d1547dac5f94f8ff5ce500b4a7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/cytokinetics-ceo-robert-blum-fda-decision-aficamten-ohcm/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CYTK"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T09:01:00+00:00",
    "headline": "Global Pulmonary Embolism Market Set for Growth with Increasing DVT and PE Cases",
    "summary": "The global pulmonary embolism market is poised for growth from 2025 to 2035, fueled by rising cases of deep vein thrombosis (DVT) and pulmonary embolism (PE) due to escalating obesity rates and sedentary lifestyles. Key drivers include improved diagnostics, Direct Oral Anticoagulants (DOACs), and heightened awareness. Despite the growth, high treatment costs and complications, such as bleeding risks, pose significant challenges, especially in lower-income regions. Top market players include Sano",
    "url": "https://finance.yahoo.com/news/global-pulmonary-embolism-market-set-090100815.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "01b9f7ad-7529-3a07-953c-137147ab6314",
      "content": {
        "id": "01b9f7ad-7529-3a07-953c-137147ab6314",
        "contentType": "STORY",
        "title": "Global Pulmonary Embolism Market Set for Growth with Increasing DVT and PE Cases",
        "description": "",
        "summary": "The global pulmonary embolism market is poised for growth from 2025 to 2035, fueled by rising cases of deep vein thrombosis (DVT) and pulmonary embolism (PE) due to escalating obesity rates and sedentary lifestyles. Key drivers include improved diagnostics, Direct Oral Anticoagulants (DOACs), and heightened awareness. Despite the growth, high treatment costs and complications, such as bleeding risks, pose significant challenges, especially in lower-income regions. Top market players include Sano",
        "pubDate": "2025-12-19T09:01:00Z",
        "displayTime": "2025-12-19T09:01:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/global-pulmonary-embolism-market-set-090100815.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/global-pulmonary-embolism-market-set-090100815.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SNY"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-19T14:40:03+00:00",
    "headline": "Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term",
    "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
    "url": "https://finance.yahoo.com/news/why-bristol-myers-squibb-bmy-144003728.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "68ab6bfc-4f39-32c9-bf38-79e454dfe591",
      "content": {
        "id": "68ab6bfc-4f39-32c9-bf38-79e454dfe591",
        "contentType": "STORY",
        "title": "Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term",
        "description": "",
        "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
        "pubDate": "2025-12-19T14:40:03Z",
        "displayTime": "2025-12-19T14:40:03Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/71afbbc0512eb3c471136d93f39079c9",
          "originalWidth": 900,
          "originalHeight": 600,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Ucluz4bedY7Dxd_XS4xCHQ--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/71afbbc0512eb3c471136d93f39079c9.cf.webp",
              "width": 900,
              "height": 600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Asv6z7WU__xaJFJkAJhxZQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/71afbbc0512eb3c471136d93f39079c9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-bristol-myers-squibb-bmy-144003728.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-bristol-myers-squibb-bmy-144003728.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]